BNP Paribas Arbitrage SA decreased its position in CVS Health Corporation (NYSE:CVS) by 16.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,152 shares of the pharmacy operator’s stock after selling 56,719 shares during the period. BNP Paribas Arbitrage SA’s holdings in CVS Health Corporation were worth $26,355,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of CVS. Acrospire Investment Management LLC raised its position in shares of CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock valued at $102,000 after buying an additional 900 shares during the last quarter. MU Investments Co. Ltd. raised its position in shares of CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock valued at $109,000 after buying an additional 440 shares during the last quarter. Pinkerton Retirement Specialists LLC raised its position in shares of CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock valued at $110,000 after buying an additional 1,112 shares during the last quarter. D Orazio & Associates Inc. raised its position in shares of CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 100 shares during the last quarter. Finally, Cantab Capital Partners LLP raised its position in shares of CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock valued at $113,000 after buying an additional 924 shares during the last quarter. Hedge funds and other institutional investors own 80.63% of the company’s stock.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

CVS Health Corporation (NYSE:CVS) traded down 0.31% on Friday, reaching $74.04. The company had a trading volume of 7,498,481 shares. CVS Health Corporation has a 12-month low of $69.30 and a 12-month high of $106.67. The stock has a market capitalization of $78.96 billion, a PE ratio of 15.87 and a beta of 0.88. The stock’s 50 day moving average price is $85.54 and its 200-day moving average price is $93.77.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 EPS for the quarter, beating the consensus estimate of $1.57 by $0.07. The company had revenue of $44.60 billion for the quarter, compared to the consensus estimate of $45.29 billion. CVS Health Corporation had a net margin of 2.96% and a return on equity of 17.18%. The firm’s revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.28 EPS. Equities analysts expect that CVS Health Corporation will post $5.81 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, November 3rd. Investors of record on Monday, October 24th were issued a dividend of $0.425 per share. The ex-dividend date was Thursday, October 20th. This represents a $1.70 annualized dividend and a yield of 2.30%. CVS Health Corporation’s payout ratio is 36.40%.

A number of brokerages recently weighed in on CVS. Credit Suisse Group AG restated an “outperform” rating and set a $110.00 price objective (down previously from $115.00) on shares of CVS Health Corporation in a research report on Tuesday, October 4th. Robert W. Baird dropped their price objective on CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating on the stock in a research note on Monday, October 3rd. Leerink Swann reissued an “outperform” rating and issued a $105.00 price objective (down from $110.00) on shares of CVS Health Corporation in a research note on Sunday, October 2nd. Vetr raised CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $98.36 price objective on the stock in a research note on Monday, October 24th. Finally, Mizuho reissued a “buy” rating and issued a $111.00 price objective on shares of CVS Health Corporation in a research note on Friday, September 30th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $106.24.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.